Thursday, March 28, 2024 10:05:54 AM
It is valuable to hear input from a historical perspective, so any tidbits to consider positive or negative should always be welcome. From a cursory look, it appears they have been working on addressing these unmet pharma needs for a decade. Lack of funding and failure is expected and looks to be experienced historically.
IMO, I see two very plausible and positive paths they are currently on.
In regards to OSA, I think newer technology related to nanotech and controlled release is logically more likely to help overcome the past trials where it appears the path was correct, but ability to get to finish line more than uncertain to unlock the investment risk. It appears the new approach makes more sense and is much more possible for success. Couple it with some improved financing options in place, I think they are on to something. I think everyone would be curious as to a status update of that program.
In regards to Epilepsy/Pain candidate drug. All the DD, whether interviews, independent publications or commentary appears extremely enthusiastic and optimistic. Clearing the NIH hurdles in presumably robust preclinicals is more than promising. Considering the opioid crisis and national headlines, and the current progress in the NIH program, one can imagine the possibilities here far exceed historical comparable OTC pharmas.
IMO, the speculative value is much much higher than current reflections in the market so I will accumulate over time.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM